NDA 216593 · Nova Labs LTD
Xromi
Hydroxyurea · Oral · Antimetabolite
Priority reviewOrphanLast checked: Nov 19, 2026Latest source record: Dec 23, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2024
Apr 4, 2024
Approved uses
2
Original approval plus efficacy supplements
Registered trials
283
72 Phase 3, 37 recruiting
FAERS reports
14,936
10,721 serious, 2,099 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: MYELOSUPPRESSION and MALIGNANCIES Myelosuppression: XROMI may cause severe myelosuppression. Do not give if bone marrow function is markedly depressed. Monitor blood counts at baseline and throughout treatment. Interrupt treatment and reduce dose as necessary [see Warnings and Precautions(5.1) ] . Malignancies: Hydroxyurea is carcinogenic. Advise sun protection and monitor patients for malignancies [see Warnings and Precautions (5.3) ] . WARNING: MYELOSUPPRESSION and MALIGNANCIES See full prescribing information for complete boxed warning. Myelosuppression: XROMI may cause severe myelosuppression. Do not give if bone marrow function is markedly depressed. Monitor blood counts at baseline and throughout treatment. Interrupt treatment and reduce dose as necessary ( 5.1 ) . Malignancies Hydroxyurea is carcinogenic. Advise sun protection and monitor patients for malignancies ( 5.3...
What it is approved for
From the label in effect Feb 2, 2026.
XROMI is indicated to reduce the frequency of painful crises and reduce the need for blood transfusions in pediatric patients aged 6 months of age and older with sickle cell anemia with recurrent moderate to severe painful crises. XROMI is an antimetabolite indicated to reduce the frequency of painful crises and reduce the need for blood transfusions in pediatric patients aged 6 months of age and older with sickle cell anemia with recurrent moderate to severe painful crises. (1)
Mechanism: The precise mechanism by which hydroxyurea produces its cytotoxic and cytoreductive effects is not known. However, various studies support the hypothesis that hydroxyurea causes an immediate inhibition of DNA synthesis by acting as a ribonucleotide reductase inhibitor, without interfering with the synthesis of ribonucleic acid or of protein. The mechanisms by which XROMI produces its beneficial effects in patients with sickle cell anemia are uncertain. Known pharmacologic effects of XROMI that may contribute to its beneficial effects include increasing HbF levels in red blood cells (RBCs),...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Dec 23, 2024 Original approval · Efficacy · priority review OrphanLetterLabelMedication Guide
- Apr 4, 2024 Original approval · Type 3 - New Dosage Form · priority review OrphanLetterLabelReview
1 products under this application
- XROMI · HYDROXYUREA 100MG/ML · SOLUTION, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Hydroxyurea" as an intervention, any sponsor and status, largest first.
- Study of Biomarker-Based Treatment of Acute Myeloid LeukemiaPivotal-lookingRecruiting
Beat AML, LLCAcademic, hospital or other
NCT03013998 · 3,000 participants (planned) · Start Nov 2016 · Primary completion Dec 2032
Drug: Samalizumab (BAML-16-001-S1); BI 836858 (BAML-16-001-S2) and 45 more · For: Previously Untreated Relapsed Refractory Acute Myeloid Leukemia
Sites: Phoenix, Arizona; Scottsdale, Arizona; Los Angeles, California · 31 sites in all
- Hydroxyurea Versus Aspirin and Hydroxyurea in Essential ThrombocythemiaPivotal-lookingStatus unknown
Assistance Publique - Hôpitaux de ParisAcademic, hospital or other
NCT02611973 · 2,250 participants (planned) · Start Mar 10, 2016 · Primary completion Nov 2019
Drug: Hydroxyurea treatment (HU) · For: MPN; Essential Thrombocythemia
Sites: Créteil, France
- Intensive Compared With Nonintensive Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia or Myelodysplastic SyndromePivotal-lookingCompleted
Leukemia Research FundAcademic, hospital or other
NCT00005823 · 2,000 participants (planned) · Start Dec 1998
Drug: cytarabine; daunorubicin hydrochloride and 7 more · For: Leukemia; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Neoplasms
Sites: Birmingham, United Kingdom; London, United Kingdom; Cardiff, United Kingdom
Heidelberg UniversityAcademic, hospital or other
NCT00055874 · 1,551 participants · Start Jun 2002 · Primary completion Mar 31, 2012
Drug: recombinant interferon alfa; cytarabine and 2 more · For: Leukemia
Sites: Aachen, Germany; Aurich, Germany; Bad Hersfeld, Germany · 66 sites in all
- Primary Thrombocythaemia 1 TrialPivotal-lookingCompleted
University of CambridgeAcademic, hospital or other
NCT00175838 · 1,398 participants · Start Jul 1997 · Primary completion Nov 2016
Drug: Hydroxyurea; Aspirin · For: Thrombocythemia; Myeloproliferative Disorder
Sites: Cambridge, United Kingdom
- Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous LeukemiaPivotal-lookingCompleted
Novartis PharmaceuticalsNovartis (NVS)
NCT00333840 · 1,106 participants · Start Jun 2000 · Primary completion Mar 2012
Drug: imatinib mesilate; interferon-alpha (INF-a) and 1 more · For: Chronic Myelogenous Leukemia
Sites: Birmingham, Alabama; Montgomery, Alabama; Tucson, Arizona · 163 sites in all
- Chemotherapy and Biological Therapy With or Without Bone Marrow or Peripheral Stem Cell Transplant in Treating Patients With Chronic Myelogenous LeukemiaPivotal-lookingStatus unknown
III. Medizinische Klinik MannheimAcademic, hospital or other
NCT00025402 · 1,000 participants (planned) · Start Jul 1997
Drug: filgrastim; recombinant interferon alfa and 6 more · For: Leukemia
Sites: Brno, Czechia; Aachen, Germany; Aalen, Germany · 188 sites in all
- A Study to Evaluate Various Combinations of Anti-HIV Medications to Treat Early HIV InfectionCompleted
National Institute of Allergy and Infectious Diseases (NIAID)NIH
NCT00000919 · 900 participants
Drug: Indinavir sulfate; Lamivudine/Zidovudine and 10 more · For: HIV Infections
Sites: Birmingham, Alabama; Los Angeles, California; Menlo Park, California · 80 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- off label use1,805
- sickle cell anaemia with crisis1,246
- fatigue1,160
- diarrhoea1,111
- nausea1,007
- headache834
- death786
- product dose omission issue771
- drug ineffective745
- haemoglobin decreased682
- anaemia676
- pain651
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 91 |
| 2005 | 99 |
| 2006 | 141 |
| 2007 | 140 |
| 2008 | 141 |
| 2009 | 151 |
| 2010 | 187 |
| 2011 | 251 |
| 2012 | 340 |
| 2013 | 219 |
| 2014 | 379 |
| 2015 | 465 |
| 2016 | 718 |
| 2017 | 873 |
| 2018 | 1,087 |
| 2019 | 958 |
| 2020 | 1,256 |
| 2021 | 1,456 |
| 2022 | 1,589 |
| 2023 | 1,439 |
| 2024 | 1,143 |
| 2025 | 1,058 |
| 2026 | 755 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study.
Gisslinger H, Klade C, Georgiev P, et al. · Lancet Haematol 2020 · Clinical Trial, Phase III, Comparative Study
- A Phase 3 Trial of l-Glutamine in Sickle Cell Disease.
Niihara Y, Miller ST, Kanter J, et al. · N Engl J Med 2018 · Clinical Trial, Phase III, Multicenter Study
- A randomized phase 3 trial of interferon-α vs hydroxyurea in polycythemia vera and essential thrombocythemia.
Mascarenhas J, Kosiorek HE, Prchal JT, et al. · Blood 2022 · Clinical Trial, Phase III, Randomized Controlled Trial
- Hydroxyurea (hydroxycarbamide) for sickle cell disease.
Rankine-Mullings AE, Nevitt SJ · Cochrane Database Syst Rev 2022 · Systematic Review
- Ruxolitinib versus standard therapy for the treatment of polycythemia vera.
Vannucchi AM, Kiladjian JJ, Griesshammer M, et al. · N Engl J Med 2015 · Clinical Trial, Phase III, Comparative Study
- Hydroxyurea (hydroxycarbamide) for transfusion-dependent β-thalassaemia.
Ansari SH, Lassi ZS, Khowaja SM, et al. · Cochrane Database Syst Rev 2019 · Research Support, Non-U.S. Gov't, Systematic Review
Sponsor: Nova Labs LTD
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.